There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Edwards Lifesciences (EW – Research Report), Envista Holdings (NVST – Research Report) and CureVac (CVAC – Research Report) with bullish sentiments.
Edwards Lifesciences (EW)
Jefferies analyst Matthew Taylor maintained a Buy rating on Edwards Lifesciences yesterday and set a price target of $100.00. The company’s shares closed last Monday at $76.06, close to its 52-week low of $67.13.
According to TipRanks.com, Taylor is a 5-star analyst with an average return of 12.6% and a 63.8% success rate. Taylor covers the Healthcare sector, focusing on stocks such as Becton Dickinson, Inari Medical, and LivaNova.
Currently, the analyst consensus on Edwards Lifesciences is a Moderate Buy with an average price target of $84.77.
See today’s best-performing stocks on TipRanks >>
Envista Holdings (NVST)
Jefferies analyst Brandon Couillard maintained a Buy rating on Envista Holdings yesterday and set a price target of $44.00. The company’s shares closed last Monday at $37.95.
According to TipRanks.com, Couillard is a top 100 analyst with an average return of 22.8% and a 71.0% success rate. Couillard covers the Healthcare sector, focusing on stocks such as DENTSPLY SIRONA, Exact Sciences, and Agilent.
Currently, the analyst consensus on Envista Holdings is a Strong Buy with an average price target of $44.33.
CureVac (CVAC)
In a report released yesterday, Eun Yang from Jefferies maintained a Buy rating on CureVac, with a price target of $21.00. The company’s shares closed last Monday at $11.58.
According to TipRanks.com, Yang is a 4-star analyst with an average return of 5.1% and a 50.9% success rate. Yang covers the Healthcare sector, focusing on stocks such as Taysha Gene Therapies, Prime Medicine, Inc., and Blueprint Medicines.
CureVac has an analyst consensus of Moderate Buy, with a price target consensus of $19.17, implying a 59.8% upside from current levels. In a report issued on January 19, UBS also upgraded the stock to Buy with a $18.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on EW: